福森藥業(01652.HK)在中國獨家代理DERMAQUAL SARL水光針產品
格隆匯8月24日丨福森藥業(01652.HK)宣佈,於2021年8月20日,公司(作為分銷商)與獨立第三方DERMAQUAL SARL(作為供應商)訂立分銷協議,據此,公司擁有在中國分銷、外判分銷及銷售由供應商供應的水光針產品的獨家權利。
水光針產品屬注射類醫美產品,主要包含非交聯透明質酸。水光針為時下最受歡迎的醫美產品之一,在提升皮膚的保濕鎖水度,減少皺紋,美白抗衰老,溶脂,生髮及淡化黑眼圈等各方面的表現凸顯優勢。水光針產品可用於身體不同部位,如面部、眼部、頸部及臀部等。
據悉,供應商為一家位於法國巴黎的醫學美容產品實驗室,是歐洲醫學美容產品領先供應商之一。
董事認為,水光針產品於中國商業化後將具有良好的市場前景。公司亦將負責在中國推廣水光針產品,其中包括但不限於舉行社交媒體活動及製作公司自身的廣吿材料。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.